stonks4u
Sign up free
SLIM logo

SLIM The Obesity ETF

NASDAQ Global Select · Asset Management - Global · Financial Services

$33.25
-2.91 (-8.06%)

This investment fund aims to mirror the performance, prior to fees and expenses, of a specific benchmark index. This index is designed to track companies worldwide that are poised to generate revenue from addressing or serving the obese population. These companies span various sectors, including biotechnology, pharmaceuticals, healthcare, and medical device firms primarily focused on obesity and i…

Market Cap: $11.34M

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

95
95
Aug 7Aug 7

Quote

Day Range
$33.00 – $36.62
52-Week Range
$33.00 – $43.40
Volume
$6.3K
Market Cap
$11.34M
50-Day Avg
$33.17
200-Day Avg
$33.17
Prev Close
$36.16
Open
$35.36

Valuation & Ratios

P/E Ratio
—
EPS
—
P/B Ratio
—
P/S Ratio
—
Debt/Equity
—
Current Ratio
—
Dividend Yield
—
Gross Margin
—

Returns & Efficiency

Return on Equity
—
Return on Assets
—
FCF Yield
—
EV/EBITDA
—

Social Signal Score

45
5d
—
30d
45
1 mentions
—
60d
45
1 mentions
—
90d
45
1 mentions
—
news: 1

Valuation

SLIMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsseekingalpha.com·7d ago·Neutral

    Eli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion Eli Lilly and Company delivered a monumental Q2 2026, with revenues up 48% to $23 billion, driven by MOUNJARO and ZEPBOUND. I maintain a 'Strong Buy' rating on the company, citing robust double-digit growth in key drugs and successful pipeline expansion, including positive phase 3 retatrutide data. EBGLYSS achieved 131% YoY sales growth and secured a label expansion, offering the only 6-dose annual mainte

    View source ↗